Site Search

The Problem Many cancer patients take multiple drugs as part of their treatment – often for many months or years. While drugs are not the only costly part of cancer treatment, finding ways to reduce these costs for patients and payers will significantly reduce the overall cost burden of cancer. Biosimilars and generics are lower cost alternative versions to some cancer drugs that may become available after the ... and her insurer nearly $75,000 over two years. If she had access to a biosimilar, those overall costs would have decreased by over 20%.  ACS CAN Fights for Solutions ACS CAN supports efforts to ensure biosimilar and generic drugs are available to patients either through prescription from ...

Overview: The American Cancer Society Cancer Action Network (ACS CAN) established Survivor Views in January 2019. The project has established a cohort of 3,055 cancer patients and survivors diagnosed with and/or treated for cancer within the last five years who are willing to share their opinions ... In October 2019, Survivor Views conducted a cohort survey focused on their experiences accessing and paying for cancer care, including the cost of prescription drugs and their experiences receiving surprise bills. One thousand three hundred and ninety-two cohort members responded to ...

... 30, 2023, Judge O’Connor released a final opinion on remedies in Braidwood Management vs. Becerra , a case regarding the constitutionality of the ACA’s coverage of United States Preventive Services Task Force (USPSTF) recommended preventive services. [1] The ACA added section 2713 to ... Health Service Act (“Section 2713”) which requires, among other things, that certain plans cover USPSTF A and B recommended services with no cost-sharing. In his final opinion, Judge O’Connor ruled that plans would only be required to cover USPSTF A and B recommended services with no ... preventive services that existed as of March 23, 2010, discount the latest evidence around effective cancer prevention and early detection. ACS CAN created a chart comparing the current USPSTF recommendations to those that were in place as of March 23, 2010, showing the differences in the ...

Background Breast cancer is the second most diagnosed cancer among women in the U.S. and the second leading cause of cancer death among women after lung cancer. In 2023, an estimated 297,790 women in the U.S. will be diagnosed with invasive breast cancer, and ... Black women are more likely to experience longer intervals between mammograms and between abnormal results and follow-up. Some insurers apply cost sharing when initial breast cancer screening requires additional follow-on testing to determine whether an individual has cancer, or if dense ... and diagnostic services include but are not limited to 2D or 3D mammograms, breast ultrasounds, or breast magnetic resonance imaging.    ACS CAN’s Position ACS CAN supports H.R. 3086 to increase access to no cost breast cancer screening, diagnostic and follow-up testing. ACS CAN ...